Companies/MediciNova, Inc.

Company profile

MediciNova, Inc.

NASDAQ: MNOV · Healthcare · Biotechnology

PublicHQ La Jolla, CACIK 0001226616Reports USD

#938 of 1,394 Healthcare companies by revenuebottom-quartile growth

EA Score

43D

FH 50DQ 45GM 10SS 56

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, listing tenure · ↓ growth stability, 3-yr revenue growth

Methodology →

Revenue TTM

$596.6k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$12.0M

Employees

Market cap

$70.4M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$409.7k$409.7k2025

Net income-$12.0M-$12.0M2025

Operating income-$13.3M-$13.3M2025

Total assets$45.6M$45.6M2025

Liabilities$4.0M$4.0M2025

Equity$41.6M$41.6M2025

Revenue trend

FY2012 – FY2025 · USD

$494.0k

FY12

$84.0k

FY12

$2.4M

FY12

$3.0k

FY13

$6.0M

FY13

$4.0M

FY21

$1.0M

FY23

$409.7k

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

MediciNova, Inc. booked $409.7k in FY2025 revenue, contracting 59% year over year — slower than 85% of Healthcare companies we track, at a -2928.8% net margin.

Peers · Healthcare

XBiotech Inc.47D Heron Therapeutics, Inc.58C Spruce Biosciences, Inc.38D Pliant Therapeutics, Inc.49D

Key facts

CEOYuichi Iwaki

SectorHealthcare

IndustryBiotechnology

HeadquartersLa Jolla, CA

ExchangeNASDAQ: MNOV

Employees13

IPO date2006-12-08

Latest filings

8-K2026-06-24 10-Q2026-05-14 DEF 14A2026-04-29 10-K2026-03-10 8-K2026-02-20 8-K2025-12-30 10-Q2025-11-12 10-Q2025-08-14

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.